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ORIGINAL CONTRIBUTION
Long-Term Incidence of Stroke and Dementia in 
ASCOT
William N. Whiteley , PhD; Ajay K. Gupta , PhD; Thomas Godec , MSc; Somayeh Rostamian , PhD;  
Andrew Whitehouse, MBBS; Judy Mackay, MRCP; Peter S. Sever, PhD
BACKGROUND AND PURPOSE: Management of stroke risk factors might reduce later dementia. In ASCOT (Anglo-Scandinavian 
Outcome Trial), we determined whether dementia or stroke were associated with different blood pressure (BP)–lowering 
regimens; atorvastatin or placebo; and mean BP, BP variability, and mean cholesterol levels.
METHODS: Participants with hypertension and ≥3 cardiovascular disease risk factors were randomly allocated to amlodipine- 
or atenolol-based BP-lowering regimen targeting BP <140/90 mm Hg for 5.5 years. Participants with total cholesterol ≤6.5 
mmol/L were also randomly allocated to atorvastatin 10 mg or placebo for 3.3 years. Mean and LDL (low-density lipoprotein) 
cholesterol, BP, and SD of BP were calculated from 6 months to end of trial. UK participants were linked to electronic health 
records to ascertain deaths and hospitalization in general and mental health hospitals. Dementia and stroke were ascertained 
by validated code lists and within-trial ascertainment.
RESULTS: Of 8580 UK participants, 7300 were followed up to 21 years from randomization. Atorvastatin for 3.3 years had no 
measurable effect on stroke (264 versus 272; adjusted hazard ratio [HR], 0.92 [95% CI, 0.78–1.09]; P=0.341) or dementia (238 
versus 227; adjusted HR, 0.98 [95% CI, 0.82–1.18]; P=0.837) compared with placebo. Mean total cholesterol was not associated 
with later stroke or dementia. An amlodipine-based compared with an atenolol-based regimen for 5.5 years reduced stroke (443 
versus 522; adjusted HR, 0.82 [95% CI, 0.72–0.93]; P=0.003) but not dementia (450 versus 465; adjusted HR, 0.94 [95% CI, 
0.82–1.07]; P=0.334) over follow-up. BP variability (SD mean BP) was associated with a higher risk of dementia (per 5 mm Hg 
HR, 1.14 [95% CI, 1.06–1.24]; P<0.001) and stroke (HR, 1.21 [95% CI, 1.12–1.32]; P<0.001) adjusted for mean BP.
CONCLUSIONS: An amlodipine-based BP regimen reduced the long-term incidence of stroke compared with an atenolol-based 
regimen but had no measurable effect on dementia. Atorvastatin had no effect on either stroke or dementia. Higher BP 
variability was associated with a higher incidence of later dementia and stroke.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
Key Words: blood pressure ◼ cholesterol ◼ dementia ◼ risk factors ◼ stroke
Although a reduction in stroke incidence earlier in life could prevent dementia in late life,1 clinical trials of stroke-preventing therapies do not show consistent 
reduction in the incidence of dementia.2–4 Therefore, lon-
ger follow-up to ages when dementia is more common 
might be needed to detect any effect.
The long-term follow-up of trials of blood pressure (BP) 
and LDL (low-density lipoprotein) cholesterol management 
provides an opportunity to test the hypothesis that inter-
vention in earlier years reduces later dementia. Therefore, 
we sought to follow-up UK participants in ASCOT (Anglo-
Scandinavian Cardiac Outcomes Trial). ASCOT was a 2×2 
factorial randomized trial with 2 arms: a BP-lowering arm 
(BPLA) that compared amlodipine-based with atenolol-
based BP-lowering regimens and a lipid-lowering arm 
















Whiteley et al Stroke and Dementia in ASCOT
2  October 2021 Stroke. 2021;52:00–00. DOI: 10.1161/STROKEAHA.120.033489
In the original trial population, both interventions 
reduced stroke. Atorvastatin reduced all stroke (hazard 
ratio [HR], 0.73 [95% CI, 0.56–0.96]; P=0.024) after 3.3 
years of follow-up, when this trial arm stopped early for 
evidence of efficacy.5 The amlodipine-based BP-lower-
ing regimen compared with the atenolol-based regimen 
significantly reduced all stroke (HR, 0.77 [95% CI, 0.66–
0.89]; P=0.0003) after a median follow-up of 5.5 years.6
In this article, the ASCOT follow-up is extended to 21 
years and with new data ascertains both nonfatal and 
fatal stroke and dementia.7 We compare the incidence 
of stroke and dementia in UK participants allocated to 
either amlodipine-based or atenolol-based BP regimens 
(for median of 5.5 years) and atorvastatin or placebo 
(for median of 3.3 years). We estimate the association 
between in-trial (excluding the first 6 months) mean BP, 
BP variability, and mean total cholesterol with the subse-
quent incidence of stroke and dementia during follow-up.
METHODS
Data Availability
Investigators wishing to access these data need to contract 
with NHS Digital and NHS Scotland, obtain the relevant ethi-
cal and data governance permissions, and have an analysis 
environment compliant with the Data Security and Protection 
Toolkit (www.dsptoolkit.nhs.uk). Other data from this study 
(code lists, statistical code) are available. Tabular data can be 
shared with collaborators if costs for further data extraction 
and analyses can be covered, by application to the ASCOT 
chief investigator P.S.
ASCOT was a 2×2 factorial trial based in both hospital 
clinics and primary care in the United Kingdom, Ireland, and 
Nordic countries that recruited participants between 1998 and 
2002. The ASCOT BPLA6 included participants with hyperten-
sion (systolic BP ≥160 mm Hg if untreated or ≥140 mm Hg if 
treated or diastolic BP ≥100 mm Hg if untreated or ≥90 mm Hg 
if treated), who had no history of coronary heart disease, and 
≥3 risk factors for cardiovascular disease (male sex, age ≥55 
years, smoking, type 2 diabetes, peripheral artery disease, pre-
vious stroke or transient ischemic attack (TIA), left ventricular 
hypertrophy or other ECG abnormalities, microalbuminuria or 
proteinuria, ratio of plasma total cholesterol to HDL [high-
density lipoprotein] cholesterol ≥6 mmol/L, or premature family 
history of coronary heart disease). Participants were randomly 
allocated to 2 unblinded BP-lowering regimens: amlodipine 
with or without perindopril (amlodipine based) or atenolol with 
or without bendroflumethiazide (atenolol based). At each follow-
up visit, antihypertensive drug therapy was titrated to achieve 
a target BP of <140/90 mm Hg for nondiabetic patients and 
<130/80 mm Hg for diabetic patients, and information was 
recorded about adverse events and cardiovascular events.
The ASCOT LLA included participants from the BPLA trial 
who had a fasting total cholesterol of ≤6.5 mmol/L untreated 
with a cholesterol-lowering agent. Participants were randomly 
allocated to atorvastatin 10 mg or placebo.5
At the end of the period of active within-trial follow-up, 
we had no further information about BP or LDL cholesterol 
management.
We linked UK ASCOT participants from the date of trial entry 
to centrally held electronic health record (EHR) in Scotland, 
England, and Wales. We linked participants in England and 
Wales to death, hospitalization, and mental health records. In 
Scotland, we linked to death, hospitalization in general and 
mental health hospitals, and an audit of stroke care (from 
2005). We only obtained data on those participants who had 
consented for long-term mortality follow-up and had not opted 
out of use of national datasets for research use.
Measurement of BP and LDL Cholesterol
During active follow-up period of the trial (≈5.5 years), BP was 
measured in a sitting position after 5 minutes of rest 3× at 
screening, at a randomization appointment, at 1.5, 3, and 6 
months, and subsequently 6 monthly thereafter. Total and LDL 
cholesterol were measured at 6 months and annually thereaf-
ter. LDL cholesterol was calculated using the LDL-Friedewald 
formula; in participants with triglyceride >4.5 mmol/L, LDL cho-
lesterol was not estimated.
For each visit, we calculated a mean of the last 2 of 3 BP 
measures, or all measures if fewer were measured, from 6 
months after randomization (by which time BP was stable) to 
last measured BP during the trial, in all participants with at least 
3 visits for BP measurement and who were alive at the end 
of BPLA. We calculated a mean of these visit means and the 
SD of these means as a measure of visit-to-visit BP variability. 
Other measures of BP variability were closely correlated with 
SD in this dataset. We calculated mean total and LDL choles-
terol from 6 months after randomization to end of BPLA. For 
observational analyses of cholesterol, we analyzed data from 
the participants in the BPLA who did not take part in the LLA 
(Figure I in the Data Supplement).
Identification of Stroke and Dementia
Stroke was identified by investigators during the course of 
the trial and in EHR with previously validated code lists during 
and after the trial.8 Dementia was identified in EHR during 
and after the trial with previously validated code lists (Data 
Supplement).9 For all outcomes, we measured time to the first 
recorded outcome reported by either investigators or EHR. 
During the trial, stroke outcomes were adjudicated by a panel, 
but there was no further adjudication of stroke or dementia 
diagnoses recorded in EHR.
We use all stroke as the principal stroke outcome and where 
available analyzed ischemic stroke, hemorrhagic stroke (both 
subarachnoid hemorrhage and intracerebral hemorrhage), 
Nonstandard Abbreviations and Acronyms
ASCOT  Anglo-Scandinavian Cardiac Outcomes 
Trial
BP blood pressure
BPLA blood pressure lowering arm
EHR electronic health record
HDL high-density lipoprotein
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stroke of unspecified type, TIA, or retinal artery occlusion and 
all of these outcomes as a composite, cerebrovascular disease.
We used all dementia as the principal dementia outcome, and 
analyzed vascular dementia, Alzheimer disease, and unknown or 
rare dementia in mutually exclusive categories, as recorded in 
the EHR. No further adjudication of records was possible.
Statistical Analyses
We analyzed all UK participants in ASCOT. Where linkage was 
not possible (largely because they had not consented to long-
term mortality follow-up), we censored participants at the end 
of trial follow-up period.
We compared stroke and dementia incidence between 
participants in their allocated treatment groups and between 
participants with higher and lower baseline and mean LDL and 
total cholesterol and SD of BP.
We used Cox proportional hazards regression analysis 
to conduct survival analysis, tested the proportional hazards 
assumption, and reported the HR, its 95% CI, and P. Our prin-
cipal analyses were for all-cause stroke and all-cause demen-
tia. Censoring took take place on death, withdrawal of consent, 
date of end of linkage period, and out-migration. Follow-up time 
for observational analyses began at the end of trial, 5.5 years 
after randomization.
We report analyses unadjusted and adjusted for age, sex, 
baseline systolic BP, body mass index, age left education, his-
tory of diabetes, and smoking risk factors at baseline. We fur-
ther adjusted SD of BP for mean BP analyses. We looked for 
evidence of effect modification by age, sex, ethnicity, baseline 
BP, total cholesterol, body mass index, and diabetes.
Stata 16 was used for all analyses.
Ethical and Other Permissions
We obtained approval from the South East Scotland Research 
Ethics Committee (18/SS/0016), the Health Research 
Authority Confidentiality Advisory Group (18/CAG/0044), the 
Independent Group Advising on the Release of Data of NHS 
Digital, and the Public Benefit and Privacy Panel for Health 
and Social Care of NHS Scotland. We prepared this report 
with reference to the Reporting of Studies Conducted Using 
Observational Routinely Collected Health Data Statement 
(Table VII in the Data Supplement).10
RESULTS
In ASCOT, 8580 participants were from England, Wales, 
or Scotland, of whom 7300 were flagged at the end of 
the trial (Figure 1). Participants were followed up for a 
median of 17 years (interquartile range, 9–19) to a maxi-
mum of 21 years.
The UK participants were well matched by allocated 
group. On average, participants were 64 years of age 
(SD, 8) at trial entry, and the majority were men (81% in 
BPLA and 87% in LLA) and had left education before 
16 years of age (79%). At baseline, BP was 162/92 
mm Hg (SD, 18/10) and mean total cholesterol was 5.9 
mmol/L (SD, 1.1) in BPLA and 5.5 mmol/L (SD, 0.8) in 
LLA. Participants had a history of diabetes (29%), stroke 
or TIA (12%), or other vascular disease (17%; Table 1). 
Compared with non-UK participants at baseline, UK 
participants were on average slightly older, less likely to 
smoke, drank more alcohol per week, with less time in 
education, and fewer had a history of vascular disease 
(Table I in the Data Supplement).
From 6 months to the end of trial, participants allo-
cated to an amlodipine-based regimen had a mean 
BP of 136 (SD, 10) mm Hg with a mean SD of all BP 
measurements of 11 mm Hg compared with, for the 
Figure 1. Consolidated Standards of Reporting Trials diagram.
ASCOT BPLA indicates Anglo-Scandinavian Outcome Trial–Blood Pressure Lowering Arm; ASCOT LLA, Anglo-Scandinavian Outcome Trial–
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atenolol arm, 138 (SD, 11) mm Hg with a mean of SD 
of all measurements of 13 mm Hg.
During follow-up, 965 (11%) participants had a fatal 
or nonfatal stroke: 359 (4%) first strokes of uncertain 
type, 610 (7%) first ischemic strokes, 117 (1%) first 
intracerebral hemorrhages, 30 (<1%) first subarachnoid 
hemorrhages, 252 (3%) first TIAs, and 33 (<1%) first 
retinal artery embolisms (each participant could have >1 
stroke type). Dementia was recorded in 915 participants: 
unknown type (381; 42%), vascular dementia (294; 
32%), Alzheimer disease (221; 24%), and rare demen-
tias (19; 2%). Nonfatal stroke during follow-up was asso-
ciated with increased odds of later dementia (142/771 
participants with stroke and 773/7809 participants with 
no stroke; OR, 2.05 [95% CI, 1.69–2.50] and P<0.001; 
adjusted OR, 1.67 [95% CI, 1.36–2.05] and P<0.001).
Participants allocated to atorvastatin rather than pla-
cebo for 3.3 years had nonsignificantly fewer fatal or 
nonfatal strokes during 21 years follow-up (272 pla-
cebo and 264 atorvastatin; adjusted HR, 0.92 [95% 
CI, 0.78–1.09]; P=0.341; Figure 2A; Figure II in the 
Data Supplement) There was no effect modification by 
any prespecified subgroup, different effect on different 
stroke types (interaction by stroke type P=0.907), or 
interaction with allocation to BP regimens (P=0.522; 
Table II in the Data Supplement).
Compared with participants allocated to placebo, 
those allocated to atorvastatin had a similar incidence 
Table 1. Baseline Characteristics of UK Participants in LLA and BPLA by Allocated Groups
Characteristic  n (%), mean (SD), or median (IQR)
  BPLA LLA
  Atenolol (n=4275) Amlodipine (n=4305) Placebo (n=2288) Atorvastatin (n=2317)
Age at randomization, y  64 (8) 64 (8) 64 (8) 64 (8)
Sex Male 3468 (81.1%) 3492 (81.1%) 2004 (87.6%) 2016 (87.0%)
Ethnicity White/European 3840 (89.8%) 3861 (89.7%) 2019 (88.2%) 2045 (88.3%)
 South Asian 109 (2.5%) 130 (3.0%) 80 (3.5%) 72 (3.1%)
 East Asian 3 (0.1%) 7 (0.2%) 2 (0.1%) 2 (0.1%)
 Mixed/other 86 (2.0%) 85 (2.0%) 33 (1.4%) 36 (1.6%)
 African 237 (5.5%) 222 (5.2%) 154 (6.7%) 162 (7.0%)
 Age left full-time education* 12–14 y 1272 (29.6%) 1282 (30.0%) 658 (28.4%) 682 (29.8%)
15–16 y 2165 (50.3%) 2091 (48.9%) 1119 (48.3%) 1121 (49.0%)
 17–18 y 465 (10.8%) 484 (11.3%) 287 (12.4%) 245 (10.7%)
 19+ y 400 (9.3%) 416 (9.7%) 252 (10.9%) 239 (10.5%)
Body mass index, kg/m2  28.9 (4.6) 28.9 (4.7) 28.8 (4.6) 28.8 (4.9)
Smoking status Current smoker 1006 (23.5%) 1035 (24.0%) 541 (23.6%) 547 (23.6%)
Alcohol status Nondrinker 1089 (25.5%) 1088 (25.3%) 571 (25.0%) 574 (24.8%)
 1–13 units/wk 1831 (42.8%) 1816 (42.2%) 983 (43.0%) 1010 (43.6%)
Systolic blood pressure, mm Hg  162 (17) 162 (18) 162 (18) 162 (17)
Diastolic blood pressure, mm Hg  92 (10) 92 (10) 93 (10) 92 (10)
Heart rate, bpm  71 (12) 71 (13) 71 (13) 70 (12)
Total cholesterol, mmol/L  5.9 (1.1) 5.9 (1.1) 5.5 (0.8) 5.5 (0.8)
HDL cholesterol, mmol/L  1.3 (0.4) 1.3 (0.4) 1.3 (0.3) 1.3 (0.3)
LDL cholesterol, mmol/L*  3.8 (1.0) 3.8 (1.0) 3.5 (0.8) 3.5 (0.7)
Serum triglycerides, mmol/L  1.6 (1.2–2.3) 1.6 (1.2–2.3) 1.4 (1.1–2.0) 1.4 (1.0–2.0)
Resting glucose, mmol/L*  5.6 (5.1–6.6) 5.6 (5.1–6.6) 5.6 (5.1–6.6) 5.6 (5.1–6.5)
Creatinine, umol/L*  98 (89–109) 99 (89–109) 99 (90–109) 99 (90–109)
Diabetes  1222 (28.6%) 1233 (28.6%) 668 (29.2%) 660 (28.5%)
Prior stroke/TIA  492 (11.5%) 507 (11.8%) 239 (10.4%) 233 (10.1%)
Prior cardiovascular disease  745 (17.4%) 734 (17.0%) 388 (17.0%) 346 (14.9%)
Prior peripheral vascular disease  383 (9.0%) 359 (8.3%) 150 (6.6%) 160 (6.9%)
Left ventricular hypertrophy  876 (20.5%) 936 (21.7%) 519 (22.7%) 329 (22.8%)
Prior atrial fibrillation  60 (1.4%) 60 (1.4%) 32 (1.4%) 36 (1.6%)
Missing values: 5 for age left education, 525 for LDL cholesterol, 382 for glucose, 220 for creatinine, and 52 for AF. AF indicates atrial fibrillation; BPLA, blood 
pressure lowering arm; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; LLA, lipid-lowering arm; and TIA, transient ischemic attack.
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of dementia (238 atorvastatin and 227 placebo; HR, 
0.98 [0.82–1.18]; P=0.837; Figure 2B; Figure II in the 
Data Supplement), more due to vascular dementia (98 
versus 67) than other dementia types (interaction by 
dementia diagnosis P=0.031). There was no modifica-
tion by any prespecified subgroup or interaction with 
allocation to BP regimens (P=0.076) or after excluding 
cases in the first 10.5 years of follow-up (Table III in the 
Data Supplement).
There was no significant association after adjustment 
between baseline LDL cholesterol or total cholesterol or 
mean total cholesterol with stroke or dementia or any of 
the subtypes of either (Table 2).
Participants allocated to an amlodipine-based rather 
than atenolol-based BP-lowering regimen for 5.5 
years had a significant reduction in the incidence of 
fatal or nonfatal stroke during follow-up (443 amlodip-
ine based and 522 atenolol based; HR, 0.82 [95% CI, 
0.72–0.93]; P=0.003; Figure 3A; Figure III in the Data 
Supplement). The HR was the greatest for hemor-
rhagic strokes, although the CIs on each subtype over-
lapped (Figure 3A). There was no difference between 
within-trial versus post-trial period or within-trial stroke 
recorded by trial mechanisms alone or linked records 
alone. An amlodipine-based regimen reduced stroke 
significantly more where baseline total cholesterol was 
≥6 mmol/L (P=0.019). There was no modification of 
the effect by other prespecified subgroups (Table IV 
in the Data Supplement) or by different stroke types 
(interaction by stroke type P=0.774).
There was no reduction in all dementia in participants 
allocated to an amlodipine-based BP regimen compared 
with an atenolol-based regimen (450 amlodipine and 
465 atenolol; HR, 0.94 [95% CI, 0.82–1.07]; P=0.323; 
Figure 3B; Figure III in the Data Supplement). Effects did 
not differ by reported dementia type or prespecified sub-
groups (Table V in the Data Supplement) or after exclud-
ing cases in the first 10.5 years of follow-up.
After adjustment, a higher incidence of all stroke 
was observed with a 10-mm Hg higher mean systolic 
BP (adjusted HR, 1.19 [95% CI, 1.11–1.27]; P<0.011) 
and a 5-mm Hg higher SD in BP (HR, 1.21 [95% CI, 
1.12–1.32]; P<0.001, adjusted in addition for mean BP; 
Table 2; Table VI in the Data Supplement).
After adjustment, there was no association between 
higher mean BP with later dementia (HR, 1.05 [95% CI, 
0.99–1.14]), but there was evidence of reverse causality. 
After excluding dementia cases in the first 10.5 years 
of follow-up, mean BP was associated with dementia 
(HR, 1.13 [95% CI, 1.03–1.24]; P=0.009), though at 
15.5 years, fewer cases were available (HR, 1.11 [95% 
CI, 0.96–1.27]; P=0.158). However, higher BP vari-
ability (SD of mean systolic BP) was associated with a 
higher incidence of later dementia (HR, 1.14 [95% CI, 
1.06–1.24]; P<0.001) even after adjustment for mean 
BP, particularly for vascular dementia (HR, 1.34 [95% 
CI, 1.18–1.51]; P<0.001; Table 2; Table VI in the Data 
Supplement). This was not attenuated after adjustment 
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Figure 2. Effect of allocation to atorvastatin or placebo in incidence of types of stroke and dementia.
A, Stroke; (B) dementia. HR indicates hazard ratio. *Per 1000 person-years. **Adjusted for baseline age, sex, systolic blood pressure, total 
cholesterol, body mass index, diabetes status, smoking habit, ethnicity, age left full-time education, and blood pressure lowering trial treatment 
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DISCUSSION
In this 20-year follow-up of ASCOT, an amlodipine-based 
BP-lowering regimen reduced the relative risk of stroke 
by 18% compared with an atenolol-based BP-lowering 
regimen. Although greater BP variability was associated 
with higher dementia incidence, and amlodipine-based 
regimens are associated with lower BP variability,11 we 
did not demonstrate that an amlodipine-based regimen 
for 5.5 years reduced dementia incidence after 20 years.
Participants allocated to 10-mg atorvastatin for a 
period of 3.3 years had no significant legacy of reduced 
stroke or dementia incidence over 20 years of follow-up. 
This study differs a study that did show a legacy effect 
on stroke because the trial period was shorter and the 
post-trial use of statins was greater.12
A legacy effect, that is a persistent protective effect of 
an intervention in a trial after it has stopped, is unusual 
for medications but has been observed in trials of statins 
and antihypertensives.13,14 Other than chance or bias, 
there are a number of potential causal mechanisms. 
There may be a cascade of benefit on stroke incidence 
after an early reduction in intermediate risk factors due 
to treatment, such as atrial fibrillation or endothelial dam-
age. A reduction in disabling events during trial might 
reduce events after trial through effects on reductions in 
deprivation or other effects of disability on health.
In this study, mean BP at any time was not associ-
ated with dementia after accounting for the confound-
ing effect of age. However, higher systolic BP is most 
strongly associated with dementia when measured many 
years before diagnosis,15 supported in our study by a 
significant association when mean BP was measured at 
least 10.5 years before a dementia diagnosis.
Greater BP variability was associated with higher 
dementia incidence particularly where the dementia type 
was recorded as due to vascular dementia. This is con-
sistent with previous observations in cohorts recruited 
from community, clinical trials, and electronic records.16–19 
Higher BP variability is largely due to age-related stiff-
ening of large arteries and loss of baroreflex function. 
Antihypertensive drugs have little beneficial effect in 
reducing variability, although dihydropyridine calcium 
channel blockers may have a modest effect.20
A causal effect of higher BP variability on vascular 
dementia is plausible. We may not have detected an 
influence of amlodipine-based treatment on dementia 
incidence because of the short duration of treatment, 
the modest effect of amlodipine on BP variability within 
trial, or likely similar BP treatment between groups after 
the end of trial.
We did not observe an association between higher 
mean cholesterol and all stroke nor evidence of a dif-
ferential association by stroke types. Observational asso-
ciations between higher total cholesterol and risk of all 
stroke are largely neutral,21 although higher LDL choles-
terol is associated with a higher incidence of all ischemic 
stroke and lower incidence of hemorrhagic stroke in more 
recent, large observational studies.22 The neutral associ-
ation in this study may be because misclassification of 
stroke types in UK EHRs obscured the underlying rela-
tionship. The lack of an association between earlier total 
or LDL cholesterol with later dementia is consistent with 
previous observational analyses,23 although some analy-
ses do demonstrate a positive association.24 The observed 
increase in vascular dementia with atorvastatin may be an 
effect of misclassification, or most likely chance, because 
the effect on dementia overall was neutral.
There are a number of limitations to our analyses.
First, we were unable to follow-up the entire ASCOT 
population because identifiers were not available for Scan-
dinavian, Irish cohorts, or all UK participants. Therefore, 
there may have been imbalances in unmeasured confound-
ers because randomization was not stratified by country. 
However, the sample size was large, and there was no evi-
dence of imbalance in measured confounders. Adjustment 
Table 2. Observed Association Between Mean and SD of Blood Pressure and Mean Total Cholesterol Over the Course of the 
Trial and Later Development of Stroke or Dementia
 Total N No. of cases, n (%) Crude HR (95% CI) P value Adjusted HR (95% CI)* P value
All stroke
 Mean total cholesterol (per 1 mmol/L)† 3286 279 (8.5) 0.94 (0.83–1.07) 0.358 0.99 (0.86–1.13) 0.843
 Mean systolic blood pressure (per 10 mm Hg)‡ 7092 661 (9.3) 1.25 (1.17–1.34) <0.001 1.10 (1.02–1.19) 0.011
 SD systolic blood pressure (per 5 mm Hg)‡ 7092 661 (9.3) 1.39 (1.29–1.49) <0.001 1.21 (1.12–1.32) <0.001
All dementia
 Mean total cholesterol† 3286 416 (12.7) 0.95 (0.86–1.06) 0.371 0.98 (0.88–1.10) 0.742
 Mean systolic blood pressure (per 10 mm Hg)‡ 7092 844 (11.9) 1.19 (1.12–1.26) <0.001 1.02 (0.95–1.10) 0.528
 SD systolic blood pressure (per 5 mm Hg)‡ 7092 844 (11.9) 1.33 (1.25–1.42) <0.001 1.14 (1.06–1.24) <0.001
Mean (SD) of mean total cholesterol, 5.50 (0.93) mmol/L; mean (SD) of mean SBP, 137 (10) mm Hg; mean (SD) of SD of SBP, 11.8 (4.7) mm Hg. BP indicates blood 
pressure; HR, hazard ratio; LLA, lipid-lowering arm; and SBP, systolic blood pressure.
*Baseline age, sex, SBP, total cholesterol, diabetes status, smoking habit, ethnicity, and age left full-time education. For BP measures, SD BP adjusted for mean SBP 
and mean BP adjusted for SD SBP.
†In 3286/3975 patients had at least 1 measurement post-6 mo, over a 5-y period, and were alive and in follow-up at least until 5.5 y in the LLA arm only.
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of comparisons of allocated interventions for known con-
founders made almost no difference to the results.
Second, the duration of the interventions was short 
relative to the time to dementia, and post-trial manage-
ment of BP and LDL cholesterol was likely to be similar 
between groups. If the randomly allocated treatments 
had continued for 20 years, then differences may have 
emerged, but such a study would not be practical. The 
interventions reduced all-cause mortality, stroke, and MI; 
however, higher doses of statin or more intense lower-
ing of mean BP (as in the SPRINT-MIND trial [Systolic 
Blood Pressure Intervention Trial])25 or BP variability 
might lead to a reduction in dementia incidence.
Third, stroke and dementia were identified with EHR. 
There are 2 limitations with this approach: misclassifica-
tion and underascertainment.
Misclassification was minimized with recommended 
code lists for dementia in any position and stroke in the 
first 2 positions of EHR or death records.8,26 Residual 
misclassification may still have existed (particularly for 
stroke in EHR), but we expect this to have been bal-
anced between groups, and of note, the within-trial effect 
on stroke was similar using EHR only or adjudicated 
outcomes only. Dementia in EHR probably has sub-
stantial underascertainment, but the 20-year cumulative 
dementia incidence in this study (17%) was greater than 
population-based studies using in-person follow-up (eg, 
20-year dementia incidence in men at 65 years of age 
is 7.7% in Framingham).27 In addition, the use of EHRs 
probably leads to less loss to follow-up than face-to-face 
or telephone follow-up. There may have been differences 
in classification of stroke or dementia over time, likely with 
increasing accuracy with more recent records, though 
there was no clear evidence of this in our analyses.
Fourth, although the association between stroke 
and dementia is strong (5-year cumulative poststroke 
dementia incidence of 33%28), most interventions mod-
estly reduce symptomatic stroke incidence (and poten-
tially minimal or asymptomatic strokes) and, therefore, 
expected reductions in dementia might be hard to 
detect in a study of thousands of people where only a 
small number experience a stroke.29 Therefore, despite 
the large number of dementia cases (915), this study 
may have been underpowered to detect a reduction in 
dementia incidence through this mechanism.
The long-term follow-up of a randomized trial is pos-
sible using national EHR. By including nonfatal events, 
the number of stroke was increased 5-fold from a previ-
ous analysis relying on deaths alone.7 However, current 
regulatory and data governance hurdles are substantial. 
Although the linkage was technically simple, overcoming 
these hurdles took several years.
By the end of the follow-up period, the predicted pro-
portion of the population with dementia and with a his-
tory of stroke was similar, indicating that both disabling 
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Figure 3. Effect of allocation to amlodipine-based or atenolol-based regimen blood pressure (BP) lowering on incidence of (A) 
types and subtypes of stroke and (B) dementia.
HR indicates hazard ratio. *Per 1000 person-years. **Adjusted for baseline age, sex, systolic BP, total cholesterol, body mass index, diabetes 
status, smoking habit, ethnicity, age left full-time education, and blood pressure lowering trial treatment allocation. ***Recorded intracerebral 
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In conclusion, we demonstrate the importance of BP 
control with amlodipine rather than atenolol for stroke 
prevention and that starting amlodipine about 5 years 
earlier still has an important detectable effect on stroke 
incidence over 20 years. Despite this reduction in stroke 
in incidence, there was no reduction in dementia inci-
dence, although dementia was almost as frequent as 
stroke over follow-up.
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